Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CVS Health Corporation (CVS)

Law Offices of Howard G. Smith reminds investors of the upcoming September 10, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased CVS Health Corporation (“CVS” or the “Company”) (NYSE: CVS) securities between May 3, 2023 and April 30, 2024, inclusive (the “Class Period”).

Investors suffering losses on their CVS investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com.

On August 2, 2023, CVS released its second quarter 2023 financial results, revealing that the Company was revising its diluted earnings-per-share (“EPS”) guidance range to $6.53 to $6.75 from $6.90 to $7.12, stating that operating income had decreased “primarily due to declines in the Health Care Benefits segment.” On this news, CVS’s stock price fell $2.04, or 2.7%, to close at $72.32 per share on August 3, 2023, thereby injuring investors.

Then, on November 1, 2023, CVS released its third quarter 2023 financial results and once again reduced its diluted EPS guidance range to $6.37 to $6.61 from $6.53 to $6.75.

Then, on February 7, 2024, CVS released its full year 2023 financial results, stating that, while operating income increased in 2023 compared to 2022, “[t]hese increases in operating income were partially offset by declines in the Health Care Benefits segment.” On this news, CVS’s stock price fell $0.96, or 1.3%, to close at $74.36 per share on February 8, 2024.

Then, on May 1, 2024, CVS released its first quarter 2024 financial results, stating that adjusted earnings for the year would be approximately $7 a share, down from previous expectations of at least $8.30. Additionally, the Company lowered its forecast for cash flow from operations by $1.5 billion. The Company cited increased medical costs in its Medicare insurance business as the cause of the lowered guidance.

On this news, CVS’s stock price fell $11.40, or 16.8%, to close at $56.31 per share on May 1, 2024, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the forecasts CVS used to determine plan premiums were ineffective at accounting for medical cost trends and health care utilization patterns; (2) as a result, CVS was likely to incur significant expenses to cover cost increases that were not accounted for in the Company’s forecasts and thus not covered by plan premiums; (3) accordingly, CVS had overstated the profitability of its Health Care Benefits segment; (4) contrary to Defendants’ assurances, the revenues generated from the Company’s other primary segments were insufficient to offset the negative financial impact of the increasing expenditures within the Health Care Benefits segment; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired CVS securities during the Class Period, you may move the Court no later than September 10, 2024 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240719130527/en/